Public Company News
Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China
SAN FRANCISCO and SUZHOU, China, June 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ...
2025-06-16 10:56
2408
Subgroup Analysis of Cadonilimab as First-Line Therapy for Advanced Cervical Cancer Reported in an Oral Presentation at ASCO 2025
HONG KONG, June 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") presented the subgroup analysis data from the Phase III COMPASSION-16 trial, evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody, in the first-line treatment of advanced, recurrent, or ...
2025-06-16 09:25
1704
Samsung Biologics launches drug screening services, Samsung Organoids
* Samsung Organoids to provide data-driven analysis of candidate molecules * Samsung Biologics expands service scope to include preclinical research INCHEON,South Korea, June 15, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organizat...
2025-06-16 07:30
1938
Celltrion announces U.S. FDA approval of additional presentation of STEQEYMA® (ustekinumab-stba), expanding dosing options for pediatric patients
* Approval of 45mg/0.5mL solution in a single-dose vial for subcutaneous injection expands dosing flexibility for pediatric patients with plaque psoriasis (PsO) or psoriatic arthritis (PsA) under 60kg * The FDA previously approved STEQEYMA® 45mg/0.5mL, 90mg/mL in a single-dose prefilled syrin...
2025-06-16 07:30
1865
JinkoSolar Announces Cash Dividend
SHANGRAO, China, June 13, 2025 /PRNewswire/ -- JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, today announced that its board of directors has declared a cash dividend ofUS$0.325 per ordinary...
2025-06-14 04:15
6271
VIVOTEK Earned Level 2 in TWSE's 11th Corporate Governance Evaluation, Top 5% Among NT$5-10B Cap Enterprises
MAKE TOMORROW EASIER, TODAY! AI Solutions Safeguarding a Sustainable and Safe Society TAIPEI, June 13, 2025 /PRNewswire/ -- VIVOTEK (3454-TW), the global leading security solution provider, continues to prioritize robust corporate governance. In the Taiwan Stock Exchange Corporation's Corporate...
2025-06-13 23:30
3168
TGE Pioneers an Iconic Fashion Show at the New York Stock Exchange's Trading Floor
PARIS, NEW YORK and SINGAPORE, June 13, 2025 /PRNewswire/ -- AMTD Group Inc. ("AMTD" or the "Group"), alongside The Generation Essentials Group (NYSE: TGE), a subsidiary of the Group under AMTD Digital (NYSE: HKD), jointly announced that L'OFFICIEL is proud to orchestrate a groundbreaking fashion...
2025-06-13 22:06
2610
SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging
Highlights * Topline data from Clarity's diagnostic Phase II trial, SABRE, showed that 64 Cu-SAR-Bombesin was safe, well tolerated and effective at detecting prostate cancer in patients with biochemical recurrence (BCR) who are negative or equivocal on standard-of-care (SOC) scans, including pr...
2025-06-13 21:01
2455
ZKH Group Limited Announces New Share Repurchase Program
SHANGHAI, June 13, 2025 /PRNewswire/ -- ZKH Group Limited ("ZKH" or the "Company") (NYSE: ZKH), a leading maintenance, repair and operations ("MRO") procurement service platform inChina, today announced that its board of directors has authorized a new share repurchase program under which the Comp...
2025-06-13 18:00
4780
ChipMOS ADJUSTS CASH DIVIDEND DISTRIBUTION RATIO TO APPROXIMATELY NT$1.23 PER COMMON SHARE OR APPROXIMATELY US$0.82 PER ADS
HSINCHU, June 13, 2025 /PRNewswire-FirstCall/ -- ChipMOS TECHNOLOGIES INC.
("ChipMOS" or the "Company") (Taiwan Stock Exchange:8150
2025-06-13 18:00
4702
Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine
CHENGDU, China, June 12, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Prof.Jun Shi's research team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) ha...
2025-06-13 17:02
1438
iQIYI celebrates fifth annual Golden Screenwriters' Night, advancing stronger industry ecosystem for screenwriting talent
BEIJING, June 13, 2025 /PRNewswire/ -- On June 11, iQIYI, China's leading online entertainment platform, hosted the annual Golden Screenwriters' Night, honoring 62 screenwriters and 20 outstanding works spanning films, drama series, and animation. Now in its fifth year, the event has become a sig...
2025-06-13 16:08
1917
XtalPi Announces Strategic Acquisition of Liverpool ChiroChem (LCC), Unlocking Unprecedented Power in Chemical Space Exploration
CAMBRIDGE, Mass. and LIVERPOOL, United Kingdom, June 13, 2025 /PRNewswire/ -- XtalPi, a leading life sciences and new materials R&D platform powered by quantum physics, AI and robotics, today announced its acquisition of Liverpool ChiroChem (LCC), a pioneer in automated chiral chemistry technolog...
2025-06-13 15:00
4929
PharmaResearch Spin-Off into Holding and Aesthetics Companies Approved by Board of Directors
SEONGNAM, South Korea, June 13, 2025 /PRNewswire/ -- PharmaResearch announced on June 13 that its board of directors has approved a corporate spin-off, resulting in the formation of two distinct entities: PharmaResearch Holdings, which will remain as the surviving entity focused on investment and ...
2025-06-13 14:21
1460
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions
SAN FRANCISCO and SUZHOU, China, June 12, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2025-06-13 09:00
2106
COMPAL Optimizes AI Workloads with AMD Instinct MI355X at AMD Advancing AI 2025 and International Supercomputing Conference 2025
SAN JOSE, Calif., June 12, 2025 /PRNewswire/ -- As AI computing accelerates toward higher density and greater energy efficiency, Compal Electronics (Compal; Stock Ticker: 2324.TW), a global leader in IT and computing solutions, unveiled its latest high-performance server platform: SG720-2A/ OG720...
2025-06-13 02:30
2802
Akkodis named a leader in aerospace & defense services and solutions by ISG
ISG's 2025 reports recognize Akkodis as a leader in aerospace & defense innovation, MRO & Aftermarket, and digital consulting across Europe and the U.S. ZURICH, June 12, 2025 /PRNewswire/ -- Akkodis, a global digital engineering company and Smart Industry leader, has been named a Leader byInfor...
2025-06-12 22:00
1524
TGE Presents the Year's Highly-Anticipated Suspense Thriller Movie: "She's Got No Name"
NEW YORK, PARIS and SINGAPORE, June 12, 2025 /PRNewswire/ -- AMTD Group Inc. ("AMTD" or the "Group"), alongside The Generation Essentials Group (NYSE: TGE), a subsidiary of the Group under AMTD Digital (NYSE: HKD), jointly announced that AMTD's newest movie, the highly anticipated suspense thrill...
2025-06-12 21:31
1915
Jianzhi Education Announces Plan to Implement ADS Ratio Change
BEIJING, June 12, 2025 /PRNewswire/ -- Jianzhi Education Technology Group Company Limited (the "Company" or "Jianzhi") (NASDAQ: JZ), a leading provider of digital educational content inChina, today announced that it plans to change the ratio of its American Depositary Shares ("ADSs") from current...
2025-06-12 20:00
3693
Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025
* Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL) post first-line therapy with a 24-month disease-free survival (DFS) rate of 74.2% * DZD8586 exhibited significant antitumor activity in heavily pretreated chronic l...
2025-06-12 18:13
1721
Week's Top Stories
Most Reposted
Nine Years of Impact: JULO Disburses USD 1.7 Billion in Digital Financing Across Indonesia
[Picked up by 297 media titles]
2025-12-23 14:23
ABL Bio Receives Upfront Payment for License, Research and Collaboration Agreement for Grabody Platform and Equity Investment from Lilly
[Picked up by 275 media titles]
2025-12-26 12:55The Grand Opening of Dreame Hong Kong Flagship Store Showcases Full Product Lineup
[Picked up by 270 media titles]
2025-12-21 12:42
Fijian and Chinese Scholars Gather to Discuss Bilateral Friendship and the Outlook for APEC 2026
[Picked up by 263 media titles]
2025-12-22 15:56
"Nihao China" App Launches as an All-in-One Solution for International Visitors
[Picked up by 253 media titles]
2025-12-24 17:54
